The breast cancer cell lines BT-20, BT-549, EFM-19, MCF-7, MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-436, MDA-MB-468, T-47D were purchased from ATCC. NCI-H1703 (KRAS mutant vs wild-type), DLD-1 (KRAS G13D/wt) and DWT7 (del/wt) were previously described [16 (link)]. MCF-7, MDA-MB-157, MDA-MB-231, MDA-MB-361, MDA-MB-436, MDA-MB-468 were cultivated in DMEM, BT-549, EFM-19, T-47D, NCI-H1703 in RPMI, DLD-1 and DWT7 in McCoy media, and BT-20 in Eagle’s Minimum Essential Medium, supplemented with 10% BGS, 2mM glutamine, 100 U/ml penicillin and 10% HEPES (all Sigma-Aldrich). All cell lines were cultured in a humidified incubator at 37°C and 5% CO2 and passaged for < 3 months after thawing a given frozen vial. All cell lines were tested mycoplasma free prior to the experiments (MycoAlert, Lonza) and none was ever treated for mycoplasma throughout the experiments. For 3D culture of tumor spheres, ~10,000 cells/well were grown in black round bottom polystyrene ultra-low attachment microplates (Corning) using serum-free medium composed of DMEM (Sigma-Aldrich), basic fibroblast growth factor (bFGF), and EGF (20 ng/mL each, Sigma-Aldrich), and B27 supplement (Life Technologies).
Mda mb 361
Manufactured by Merck Group
Sourced in United States
MDA-MB-361 is a cell line derived from a human breast adenocarcinoma. It is commonly used in research for the study of breast cancer.
Automatically generated - may contain errors
Lab products found in correlation
Mda mb 361, by American Type Culture Collection (6 mentions)
Skbr3, by American Type Culture Collection (5 mentions)
Mda mb 231, by American Type Culture Collection (3 mentions)
Mcf 7, by American Type Culture Collection (3 mentions)
Mcf 7, by Merck Group (3 mentions)
Bt474, by American Type Culture Collection (3 mentions)
Mda mb 231, by Merck Group (2 mentions)
Bt474, by Merck Group (2 mentions)
Sk br 3, by Merck Group (2 mentions)
Jimt 1, by Merck Group (2 mentions)
Trastuzumab, by Apexbio (2 mentions)
Penicillin streptomycin, by Merck Group (2 mentions)
Mda mb 453, by American Type Culture Collection (2 mentions)
Bt474, by Apexbio (2 mentions)
A8218, by Genentech (2 mentions)
Trametinib, by Apexbio (2 mentions)
Trastuzumab, by Genentech (2 mentions)
B27 supplement, by Thermo Fisher Scientific (1 mentions)
Bt549, by American Type Culture Collection (1 mentions)
Eagle s minimum essential medium, by Merck Group (1 mentions)
6 protocols using mda mb 361
1
Culturing Breast Cancer Cell Lines
2
Breast Cancer Cell Line Viability and Proliferation Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Four human breast cancer cell lines with different immunoprofiles, namely MDA-MB-361 (ER+ HER2+), MCF-7 (ER+ HER2-), SK-BR-3 (ER- HER2+), and MDA-MB-231 (ER- HER2-) were obtained from American Type Culture Collection (ATCC, USA) and were grown in culture flasks in HuMEC Basal Serum-free Medium (Thermo Fisher, USA) in order to prevent the influence of hormones and/or growth factors in regular serum-containing medium. For ER-positive cell lines (MDA-MB-361 and MCF-7), the cells were seeded in 96-well culture plates and incubated with various concentrations of AS extract, 17β-estradiol (0.1 µM, Sigma, USA), or the combination of 17β-estradiol (0.1 µM) and AS extract in medium for 48 h. For ER-negative cell lines (SK-BR-3 and MDA-MB-231), the cells were seeded in 96-well culture plates and treated with various concentrations of AS extract for 48 h. The cell viability and proliferative responses were determined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and bromodeoxyuridine (BrdU) cell proliferation enzyme-linked immunosorbent assay (ELISA) (Roche, USA), respectively.
3
Breast Cancer Cell Line Characterization
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Nine established breast cancer cell lines [MCF7, T47D, ZR-75-1 (estrogen receptor positive (ER+), HER2 not amplified), BT474, MDA-MB361 (ER+, HER2 amplified), SKBR3, JIMT-1 and KPL4 (ER-, HER2 amplified) and MDA-MB231 (ER-, HER2 not amplified)] were obtained from the American Type Culture Collection (ATCC, Manassas, USA). The MCF7, T47D, ZR-75-1, SKBR3, JIMT-1 and KPL4 cell lines were cultured in RPMI 1640 medium (Sigma, St. Louis, MO, USA), while the BT474, MDA-MB231 and MDA-MB361 lines were cultured in DMEM medium (Sigma). All culture media were supplemented with 10% fetal bovine serum (FBS) (Sigma), an antibiotic-antimycotic solution (1X) (Sigma) and L-glutamine (2 mM) (Invitrogen GmbH, Karslruhe, Germany). The cultures were maintained in an incubator at 37°C and 5% CO2.
4
Establishment of Trastuzumab-Resistant Breast Cancer Cell Lines
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The SKBR3, BT474, and MDA-MB-361 cell lines were purchased from the American Type Culture Collection. The JIMT-1 cell line was purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen. All cell lines were derived from HER2+ breast cancer cells. The SKBR3 cell line was maintained in McCoy’s 5A medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum. The BT474, MDA-MB-361, and JIMT-1 cell lines were maintained in DMEM/F12 (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 10% fetal bovine serum. Human umbilical vein endothelial cells (HUVECs) were purchased from PromoCell (Heidelberg, Germany) and were maintained in Endothelial Cell Growth Medium 2 (PromoCell). For generation of Tzm-resistant cell lines, SKBR3 and BT474 cells were grown in DMEM/F12 supplemented with 5% calf serum (Sigma-Aldrich), 4 μg/mL insulin (Thermo Fisher Scientific), 0.5 μg/mL hydrocortisone (Stem Cell Technologies, Vancouver, Canada), and 1 μg/mL (for SKBR3) or 2 μg/mL (for BT474) Tzm (Herceptin; Chugai Pharmaceutical, Tokyo, Japan) for over 6 months.
5
Breast Cancer Cell Line Authentication and Resistance
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Human breast cancer cell lines BT474, SK-BR-3, MDA-MB-361, and MDA-MB-453 were purchased from the ATCC at the beginning of the project in August 2018. Cell lines were cultured in DMEM (Sigma #D6429) supplemented with 10% FBS (Sigma #10500–064) and 1% penicillin/streptomycin (Sigma #P4333), except MDA-MB-361 cells which were grown in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, 2 mmol/L l -glutamine (Sigma #G7513), and 1× MEM nonessential amino acid solution (Sigma #M7145). lapatinib-resistant (LR) and trastuzumab-resistant (TR) BT474 cell lines were developed by incubation with gradually increased doses of lapatinib (APExBIO #A8218) or trastuzumab (Genentech) over a period of 4 to 5 months. Resistant cells were subsequently maintained with 0.1 μmol/L lapatinib or 50 μg/mL trastuzumab. The compounds were removed from the culture medium three to four days prior to experiments. Cell authentication was not routinely conducted given that cell lines were utilized for a maximum of 20 passages before thawing another aliquot of the same stock to maintain the original phenotype. Mycoplasma testing was not routinely performed on the cells. Trametinib was purchased from APExBIO (#A3887). For in vivo studies, lapatinib was dissolved in a buffer containing 1% Tween-80 and 5% hydroxypropyl methylcellulose just before use.
6
Establishment and Characterization of Breast Cancer Cell Line Models
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!